linjc16/ctgov huggingface dataset:
Adiponectin and Circulating Progenitor Cells (CPC) Function

Study Overview
=================
Brief Summary
-----------------
Adiponectin and exercise training contribute to the maintenance of a normal vascular tone by influencing vascular NO bioavailability and concentration and function of endothelial progenitor cells. The molecular mechanisms are only partially understood. Therefore, aim of the present study is to elucidate the effects of Adiponectin on endothelial progenitor cell migration and the underlying signaling pathways. Furthermore, the impact of exercise training on adiponectin-mediated endothelial progenitor cell migration will be investigated.

Official Title
-----------------
Adiponectin Promotes the Migration of Circulating Progenitor Cells Through p38-mediated Induction of the CXCR4 Receptor

Conditions
-----------------
Coronary Artery Disease

Intervention / Treatment
-----------------
* Other: exercise training


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ≤ 75 years of age stable coronary artery disease preserved left ventricular function physical work capacity of ≥ 50 successful elective percutaneous coronary intervention at study begin Exclusion Criteria: diabetes mellitus hypercholesterolemia untreated hypertension smoking myocardial infarction within the last 4 weeks significant stenosis of the left main coronary artery

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: exercise training<br>4 weeks of supervised physical exercise training | Other: exercise training<br>* 4 weeks supervised physical exercise training<br>|
| No Intervention: control<br>sedentary lifestyle | |
| No Intervention: healthy control<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| migratory capacity of endothelial progenitor cells towards an SDF-1 gradient |  | 4 weeks |
CLEAR Study - A Study of CellCept (Mycophenolate Mofetil) in Recipients of Kidney Transplants

Study Overview
=================
Brief Summary
-----------------
This study will compare the efficacy and safety of 2 dosing regimens of oral CellCept administered as a component of standard immunosuppressive therapy in recipients of kidney transplants. The anticipated time on study treatment is 3-12 months, and the target sample size is 100-500 individuals.

Official Title
-----------------
A Randomized, Open-label Study of the Achievement of a Mycophenolic Acid Therapeutic Window During Treatment With 2 Dosing Regimens of Oral CellCept Administered as a Component of Standard Immunosuppressive Therapy in Patients With Kidney Transplants

Conditions
-----------------
Kidney Transplantation

Intervention / Treatment
-----------------
* Drug: mycophenolate mofetil


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: adult patients >=18 years of age; recipients of a primary kidney transplant. Exclusion Criteria: positive for HIV-1, human T-cell leukemia/lymphoma virus-1 (HTLV-1), or hepatitis B surface antigen; positive for hepatitis C virus, with moderate or severe liver disease; active malignancy or history of malignancy, excluding skin cancer (basal or squamous cell) that has been adequately treated; need for maintenance corticosteroids for another condition.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br> | Drug: mycophenolate mofetil<br>* 1<br>* Other names: CellCept;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Proportion of patients achieving therapeutic window by Day 5\n |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Efficacy: Achieving therapeutic window at Day 3, maintaining therapeutic window at day of discharge, Months 1, 3, and 6\nSafety: Renal function, opportunistic infections, malignancies, and adverse events\n |  |  |
Non-responders to Antiplatelet Treatment in Acute Ischaemic Stroke)

Study Overview
=================
Brief Summary
-----------------
Determination of frequency of Clopidigrel- and Acetacylicacid-non-responders (HOTPR) in acute ischemic stroke patients.

Detailed Description
-----------------
Determination of frequency of Clopidigrel- and Acetacylicacid-non-responders (HOTPR) in acute ischemic stroke patients using the VerifyNow system.

Official Title
-----------------
NATIS: Non-responders to Antiplatelet Treatment in Acute Ischaemic Stroke

Conditions
-----------------
Acute Ischemic Stroke

Intervention / Treatment
-----------------
* Other: blood sampling for HOTPR-testing


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Suspected acute ischemic stroke and loading dose of Clopidogrel or Acetacylicacid Exclusion Criteria: Previous treatment with platelet inhibitor NOAC or Vitamin K-antagonist treatment Final diagnosis other than Ischemoc stroke or Transitoric ischemic attack

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Clopidogrel<br>Clopidogrel non-responders (HOTPR) Blood sampling for HOTPR-testing | Other: blood sampling for HOTPR-testing<br>* All subjects are tested for responderstatus using the VerifyNow System<br>|
| Acetacylicacid<br>Acetcylicacid non-responders (HOTPR), Blood sampling for HOTPR-testing | Other: blood sampling for HOTPR-testing<br>* All subjects are tested for responderstatus using the VerifyNow System<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Responder status | Platelet reactivity with PRU measurement | immediately | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Clopidogrel, acetacylic acid, antiplatelet therapy, HOTPR, VerifyNow
Cologne Register of Wearable Defibrillator (CRWD)

Study Overview
=================
Brief Summary
-----------------
The wearable cardiac defibrillator (WCD) is an alternative to the implantation of cardioverter defibrillator (ICD) for patients at high risk for sudden cardiac death (mostly bridging therapy). The Cologne register of wearable defibrillator (CRWD) is a prospective register for all patient with an indication of wearable defibrillator.

Conditions
-----------------
Myocardial Infarction, Ventricular Dysfunction, Myocarditis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult patients with an indication for wearable defibrillator Exclusion Criteria: childs

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of arrhythmic events and arrhythmic risk factors during bridging therapy with wearable defibrillator |  | 3 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Total mortality | Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] | 1 months and 3 months |
Explicit Assessment of Thromboembolic Risk and Prophylaxis for Medical Patients in Switzerland

Study Overview
=================
Brief Summary
-----------------
Until now, no risk assessment model informing about the need of thromboprophylaxis in patients admitted for an acute medical event has been validated. The goal of this project is to indirectly validate a model developed in Geneva by a non -interventional study involving the collection of patient characteristics during the hospitalization and a 3-month follow-up. These data will allow for the determination of the patient's risk, according to the Geneva model, and its validity, according the actual thrombo-embolic events, corrected for the thromboprophylaxis received. The project is multicentric in Switzerland (5-10 centers) and should involve about 1000 patients. First amendment (may 2011) : we have obtained the IRB approval for collecting data from patients who die during their hospital stay and for whom informed consent is not be possible to obtain.

Official Title
-----------------
Explicit Assessment of Thromboembolic Risk and Prophylaxis for Medical Patients in Switzerland (ESTIMATE): Evaluation of a Prediction Rule

Conditions
-----------------
Venous Thromboembolism

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients admitted (minimal stay >24 hours) to medical hospital wards Age ≥18 years Ability to give an informed consent, as informed by the physicians in charge of the patient Exclusion Criteria: Patients admitted to non-medical hospital wards Patients with therapeutic anticoagulation at hospital admission Patients admitted for a disease requiring therapeutic anticoagulation (MTE or other) Patients unable to give an informed consent, as informed by the physicians in charge of the patient Patients without signed informed consent Patients already included in this study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| hospitalization >24 hours<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| relationship between the combined rate of fatal and non-fatal symptomatic venous thromboembolism and bleeding events and the calculated risk score at 90 days after hospital admission | evaluation of the relationship between the combined rate of fatal and non-fatal symptomatic venous thromboembolism and bleeding events at 90 days after hospital admission on one hand, and the calculated risk score provided by the Geneva Risk Assessment Models (RAM) at hospital admission on the other hand | 90 days |
Ankylosing Spondylitis and Spondyloarthritis Evaluation Tool Study

Study Overview
=================
Brief Summary
-----------------
This study aims to test whether a new instrument (questionnaire) is useful for identifying patients with ankylosing spondylitis.

Official Title
-----------------
A Self-Administered Questionnaire for Early Detection of Axial Spondyloarthritis

Conditions
-----------------
Ankylosing Spondylitis, Spondylarthritis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Ability to provide informed consent Exclusion Criteria: Inability to provide informed consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Physician diagnosis of Ankylosing Spondylitis |  | 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
ankylosing spondylitis, spondylarthritis, inflammatory back pain, seronegative
Percutaneous Image Guided Video-Assisted Thoracic Surgery (VATS) Resection of Lung Lesions

Study Overview
=================
Brief Summary
-----------------
This is a phase II protocol to determine the safety and feasibility of Intraoperative CT fluoroscopy guidance for lung resection for small nodules.

Detailed Description
-----------------
This is a phase II protocol to determine the safety and feasibility of image guided CT marking for resection of small lung nodules. This is relevant because many such nodules are hard to localize for minimally invasive lung resection. It is hoped that this technology using fluoro CT capability available now in most operating room will improve safety and reliability of thoracic surgery.

Official Title
-----------------
Percutaneous Image Guided Video Assisted Thoracic Surgery (VATS) Resection of Lung Lesions

Conditions
-----------------
Lung Cancer

Intervention / Treatment
-----------------
* Procedure: Video-Assisted Thoracic Surgery (VATS) wedge resection


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: peripheral lung nodules < 3cm in size Surgical candidate Exclusion Criteria: Non surgical candidate

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: CT Marking and VATS lung wedge resection<br>Each patient with a lung nodule meeting criteria will undergo marking with fiducials followed at the same time by Video-Assisted Thoracic Surgery (VATS) lung wedge resection under CT fluoroscopy. | Procedure: Video-Assisted Thoracic Surgery (VATS) wedge resection<br> <br> * Other names: Nodules marked with fiducials such as Kopan needles under CT fluoroscopy followed by VATS wedge resection.;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0 | The patient will be monitored while in the hospital by their thoracic surgical team as well as by two research nurses named Lauren Donahue, RN and Karen Magsipoc, NP. The research nurses will document any perioperative complications and mortality that arise during the patient's stay in the hospital. | 30 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Patients Underwent a Successful Resection | Number of patients who underwent a successful resection which is measured by an accurate and appropriate resection in a given timeline | 30 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
lung nodule, lung cancer, lung mass
Aquatic Physical Therapy in Fibromyalgia

Study Overview
=================
Brief Summary
-----------------
Objective: To investigate whether patients undergoing aquatic physiotherapy in groups improve their functional capacity, by means of the distance covered in the six-minute walk test (6WT), and to compare this with a control group. Methods: Forty women that had not been practicing regular physical activity for one year were randomly allocated either to the Study Group (SG) to undergo an aquatic physiotherapy program in groups applied twice a week, including aerobic exercises, muscle strengthening and relaxation for 12 weeks, or to the Control Group (CG), which did not do any physical activity. Both groups maintained their treatment with medications. All patients underwent two evaluations: one at the start and the other after 12 weeks.

Official Title
-----------------
A Randomized Clinical Trial of Aquatic Physiotherapy Program on Functional Capacity in Patients With Fibromyalgia.

Conditions
-----------------
Fibromyalgia

Intervention / Treatment
-----------------
* Other: aquatic physical therapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients of both genders with a medical diagnosis of FS, without age restrictions and without impaired cognition, who had not been practicing regular physical activity for one year Exclusion Criteria: Presence of other rheumatic diseases and cardiovascular problems Smoking Absence of medical permission for swimming pool activities Starting other therapies, or changes to and/or discontinuation of medical treatment
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: 2<br> | Other: aquatic physical therapy<br>* The aquatic physiotherapy program for the SG was applied twice a week, in groups of six to seven people, with sessions lasting 40 minutes, over a 12-week period. The Control Group protocol included maintenance of the individuals' medication therapy and absence of any physical activity during the study period.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| functional capacity |  | 2 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Hydrotherapy,, RCT,
Evaluation the Neurocognitive Functions Among Children With Enlargement Adenoid and Tonsils, Before and After Tonsillectomy or Adenotonsillectomy

Study Overview
=================
Brief Summary
-----------------
Evaluation the Neurocognitive Functions Among Children With Enlargement Adenoid and Tonsils, Before and After Tonsillectomy or Adenotonsillectomy

Official Title
-----------------
Evaluation the Neurocognitive Functions Among Children With Enlargement Adenoid and Tonsils, Before and After Tonsillectomy or Adenotonsillectomy

Conditions
-----------------
Child Neurocognitive Function

Intervention / Treatment
-----------------
* Diagnostic Test: neuro trax system and a neurology test.


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: children between 6-18 years old. children with enlarged tonsils or adenoids. a sleep lab test before the procedure. Exclusion Criteria: children under 6 years old and above 18 years old. patience that treated in ADHD / ADDOR with other neurocognitive disorder.

Ages Eligible for Study
-----------------
Minimum Age: 6 Years
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Children With Enlargement Adenoid and Tonsils<br>Children With Enlargement Adenoid and Tonsils | Diagnostic Test: neuro trax system and a neurology test.<br>* the neurology will check the patience before and after tonsillectomy or adenotonsillectomy usung the neurotrax system, these parameters will be measured in this system : Non verbal memory, Go no go test, stroop interference, Visual spatial processing, Staged information processing speed, catch game, problem solving.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Neurocognitive Functions Among Children | neurology test using neuro trax system , to evaluate Neurocognitive Functions Among Children With Enlargement Adenoid and Tonsils, Before and After Tonsillectomy or Adenotonsillectomy | 2 years |
Reproductive Health Survivorship Care Plan Pilot

Study Overview
=================
Brief Summary
-----------------
Most young breast cancer patients undergo chemotherapy and/or endocrine therapy, treatments that impair ovarian function and result in significant reproductive health late effects. These late effects include symptoms of estrogen deprivation (e.g., hot flashes and vaginal dryness), which are distressing in young breast cancer survivors (YBCS). The goal of this pilot study is to test the feasibility of a 4-week text message based intervention on hot flashes and vaginal dryness in YBCS. YBCS will be randomized in a 1:1 ratio to the intervention (text messages on hot flash and vaginal dryness management) and control arms. All participants will be prompted to provide daily hot flash frequency and severity via text messaging. The primary hypothesis is YBCS will have high rates of daily hot flash reporting via text messaging. Secondarily, we will compare changes in hot flash frequency, hot flash severity and vagina dryness between the intervention and control arms.

Official Title
-----------------
Intervening on Reproductive Health in Young Breast Cancer Survivors

Conditions
-----------------
Breast Cancer, Hot Flashes, Vaginal Dryness, Estrogen Deprivation Symptoms

Intervention / Treatment
-----------------
* Behavioral: Text message management prompts


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Breast cancer Female Completed primary breast cancer treatment Age <=45

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Intervention<br>Text message management prompts: YBCS will receive text message prompts on how to manage hot flashes and vaginal dryness | Behavioral: Text message management prompts<br> <br> |
| No Intervention: Control<br>Control YBCS will not receive text message prompts on managing hot flashes and vaginal dryness | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Hot Flash Frequency | Median number of daily hot flashes over 4th week of study | 1 week |